Qiang Pan-Hammarström: We developed a new 24-gene expression score to identify high risk for developing refractory/relapsed lymphoma
Qiang Pan-Hammarström, Professor of Clinical Immunology and member of Nobel Assembly at the Karolinska Institute, shared on LinkedIn:
“Final paper in 2023, on lymphoma! We integrated genomic and transcriptomic data from seven cohorts comprising 2805 R-CHOP-treated diffuse large B cell lymphoma patients, including 887 cases with poor treatment outcomes within two years. Our analysis identified four preferentially mutated genes (TP53, MYD88, SPEN, MYC) in the untreated tumor samples from patients with poor outcomes. Importantly, we developed a new 24-gene expression score that can be used to identify those patients who are at high risk for developing refractory/relapsed (R/R) disease after receiving the current standard therapy.
Full text link.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023